Ocugen (FRA:2H51) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2H51 Ocugen Inc FRA:2H51
20 GF Score
Price €1.10
GF Value €0.73
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ocugen FFO per Share?

FFO per Share only applies to REITs.

FRA:2H51
20GF Score
Ocugen Inc FRA:2H51
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ocugen (FRA:2H51) Overvalued in 2026?

Based on GuruFocus' analysis, Ocugen stock appears to be overvalued. The current stock price of €1.10 is trading 50.4% above its estimated GF Value™ of €0.73. GuruFocus considers Ocugen to be Significantly Overvalued.

Key valuation signals for FRA:2H51:

  • FFO per Share:
  • GF Value™: €0.73 vs. price of €1.10 (50.4% above fair value)
  • GF Score™: 20/100 with 4 warning signs

No single metric tells the full story. See the FRA:2H51 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ocugen Business Description

Address 11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
20GF Score

Get the complete analysis for FRA:2H51

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.10
Price
€0.73
GF Value